Home

Andrew Saik

CIK 1616284 · Chief Financial Officer · last filed 2026-06-24

Andrew Saik is a Chief Financial Officer who has filed 42 SEC Form 4 insider transactions across 8 companies since 2014. The most recent filing shows the insider sold $46.5K of ARVN on Jun 24, 2026. Across all open-market trades the lifetime net is −$203.1K, making them a net seller over the disclosed history. Current disclosed insider exposure totals $1.6M across reported positions.

"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.

Loading insider history…
Disclosed Exposure

$1.60M

Companies

8

Total Filings

42

Lifetime Open-Market Net

-$203.1K

Filer Profile

Reported Address
640 LEE ROAD
CHESTERBROOK, PA 19087
Profile details as reported on the filer's SEC submissions — for individual insiders the address is often in care of the issuer. Related filers are identified from jointly filed SEC submissions and shared reported addresses. View filings on SEC EDGAR.

Holdings By Company

Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
Symbol Role Shares Price Disclosed Exposure Lifetime OM Net Filings Latest Filed
ARVN Chief Financial Officer 187,432 $8.45 $1.58M -$261.6K 8 2026-06-24
MIST Director — $0.98 — $0 4 2026-06-12
INTERCEPT PHARMACEUTICALS, INC. (ICPT) Delisted EVP & Chief Financial Officer 68,265 $19.00 $1.30M $0 10 2023-09-25
VYNE Therapeutics Inc. (VYNE) Delisted Chief Financial Officer 129 $28.56 $3.7K $58.5K 4 2021-06-02
VYNE Therapeutics Inc. (MNLO) Delisted Chief Financial Officer 300,000 — — $0 2 2020-05-08
PDSB Chief Financial Officer 42,549 $0.29 $12.5K $0 3 2020-02-19
EDGE Chief Financial Officer — $51.80 — $0 4 2018-08-15
AUXILIUM PHARMACEUTICALS INC (AUXL) Delisted CFO 0 — — $0 2 2015-01-30

Recent Filings

42 filings
Insider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
Filed Symbol Action Net Shares Net $ Link
2026-06-24 ARVN Sell (S) −5,696 -$46.5K EDGAR
2026-06-23 ARVN Notice (144) −5,846 -$47.6K EDGAR
2026-06-12 MIST Grant (A) — $0 EDGAR
2026-05-13 ARVN Sell (S) −11,139 -$110.7K EDGAR
2026-05-08 ARVN Notice (144) −11,343 -$114.7K EDGAR
2026-03-02 ARVN Grant (A) +45,000 $0 EDGAR
2026-02-18 ARVN Sell (S) −5,134 -$61.0K EDGAR
2026-02-13 ARVN Notice (144) −5,134 -$61.1K EDGAR
2025-06-24 ARVN Sell (S) −5,700 -$43.4K EDGAR
2025-06-23 ARVN Notice (144) −5,927 -$43.6K EDGAR
Showing 1–10 of 42
Page 1 of 5
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.